Clinical pharmacology and efficacy of inhaled iloprost for the treatment of pulmonary arterial hypertension

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Expert Review of Clinical Pharmacology

• Publication date

  2011-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/ecp.10.136PMID 22115402
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pulmonary arterial hypertension

  2013cited by this paper
• Inhaled Iloprost

  2012cited by this paper
• Long-term therapy with inhaled iloprost in patients with pulmonary hypertension.

  2010cited by this paper
• Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.

  2010cited by this paper
• A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension.

  2010cited by this paper
• Treatment and outcome of pulmonary arterial hypertension in HIV-infected patients: a review of the literature.

  2009cited by this paper
• Review of inhaled iloprost for the control of pulmonary artery hypertension in children

  2009cited by this paper
• Mobilization of bone marrow-derived Oct-4+ SSEA-4+ very small embryonic-like stem cells in patients with acute myocardial infarction.

  2009cited by this paper
• Updated clinical classification of pulmonary hypertension.

  2009cited by this paper
• Inhalative iloprost – pharmacology and clinical application

  2009cited by this paper
• Does stem cell transplantation have a role in the management of multiple myeloma, 2009?

  2009cited by this paper
• Inhaled iloprost for the treatment of pulmonary hypertension

  2009cited by this paper
• Updated clinical classification of pulmonary hypertension.

  2009cited by this paper
• HIV-related pulmonary arterial hypertension: clinical presentation and management

  2008cited by this paper
• Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension.

  2008cited by this paper
• Prostacyclin among prostanoids.

  2008cited by this paper
• Comparison of inhaled iloprost and nitric oxide in patients with pulmonary hypertension during weaning from cardiopulmonary bypass in cardiac surgery: a prospective randomized trial.

  2008cited by this paper
• Advances in diagnosis and treatment in patients with pulmonary arterial hypertension

  2008cited by this paper
• Update in pulmonary arterial hypertension 2007.

  2008cited by this paper
• Epidemiology of pulmonary arterial hypertension.

  2007cited by this paper
• Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines.

  2007cited by this paper
• Inhaled iloprost for hepatopulmonary syndrome: improvement of hypoxemia.

  2007cited by this paper
• Epidemiology of pulmonary arterial hypertension.

  2007cited by this paper
• Treatment of pulmonary arterial hypertension in pregnancy.

  2007cited by this paper
• A USA-based registry for pulmonary arterial hypertension: 1982–2006

  2007cited by this paper
• Pulmonary arterial hypertension

  2006cited by this paper
• Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.

  2006cited by this paper
• Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension

  2006cited by this paper
• Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers

  2006cited by this paper
• Pulmonary Arterial Hypertension

  2006cited by this paper
• Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.

  2006cited by this paper
• Physiologic Basis of Respiratory Disease

  2006cited by this paper
• Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension.

  2005cited by this paper
• Pathogenesis of pulmonary arterial hypertension: the need for multiple hits.

  2005cited by this paper
• Prostacyclin and its analogues in the treatment of pulmonary hypertension.

  2004cited by this paper
• Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

  2004cited by this paper
• Prostanoids and prostanoid receptors in signal transduction.

  2004cited by this paper
• Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

  2004cited by this paper
• Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines

  2004cited by this paper
• Diagnosis and differential assessment of pulmonary arterial hypertension.

  2004cited by this paper
• Inhaled iloprost is a potent acute pulmonary vasodilator in HIV‐related severe pulmonary hypertension

  2004cited by this paper
• Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension

  2004cited by this paper
• Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

  2004cited by this paper
• Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension.

  2003cited by this paper
• Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation.

  2003cited by this paper
• 2567 Long-term survival in patients with pulmonary hypertension inhaling iloprost

  2003cited by this paper
• Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation

  2002cited by this paper
• Inhaled iloprost for severe pulmonary hypertension.

  2002cited by this paper
• Epidemiology, etiology, and prevention of lung cancer.

  2002cited by this paper
• Pharmacokinetics and metabolism of infused versus inhaled iloprost in isolated rabbit lungs.

  2002cited by this paper
• Hemodynamic effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise.

  2002cited by this paper
• Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery.

  2002cited by this paper
• Long-term treatment of pulmonary hypertension with aerosolized iloprost.

  2001cited by this paper
• Aerosolised iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment

  2001cited by this paper
• Long-term treatment of pulmonary hypertension with aerosolized iloprost.

  2001cited by this paper
• [Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension].

  2001cited by this paper
• Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension.

  2001cited by this paper
• Primary Pulmonary Hypertension in Pregnancy

  2001cited by this paper
• Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension.

  2000cited by this paper
• A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group.

  2000cited by this paper
• Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue.

  2000cited by this paper
• Aerosolized Prostacyclin and Iloprost in Severe Pulmonary Hypertension

  1996cited by this paper
• Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures.

  1992cited by this paper
• Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

  1991cited by this paper
• Pharmacokinetics of iloprost in patients with chronic renal failure and on maintenance haemodialysis.

  1990cited by this paper
• Pharmacokinetics of iloprost in patients with hepatic dysfunction.

  1990cited by this paper
• PRIMARY PULMONARY HYPERTENSION: A NATIONAL PROSPECTIVE STUDY

  1987cited by this paper
• Comparison of equimolar concentrations of iloprost, prostacyclin, and prostaglandin E1 on human platelet function.

  1987cited by this paper
• Effects of Prostacyclin and of the Stable Prostacyclin Analogue ZK 36374 on Forearm Blood Flow and Blood Platelet Behaviour in Man

  1985cited by this paper
• PRIMARY PULMONARY HYPERTENSION IN PREGNANCY.

  1964cited by this paper
• Evidence-based Clinical Practice Guidelines : Accp * Pulmonary Arterial Hypertension Screening, Early Detection, and Diagnosis Of

  year unknowncited by this paper

• Approved alkyne-containing drugs: A review of their pharmacokinetic properties and therapeutic applications.

  2025cites this paper
• Iloprost: Old and New Indications.

  2025cites this paper
• Effect of furosemide in the treatment of high-altitude pulmonary edema

  2024cites this paper
• Bioinformatics exploration of potential common therapeutic targets for systemic and pulmonary arterial hypertension-induced myocardial hypertrophy

  2023cites this paper
• Inhaled pulmonary vasodilators: a narrative review

  2020cites this paper
• Evaluation of US20150011555. An inhaled IP receptor agonist for the treatment of pulmonary arterial hypertension

  2015cites this paper
• Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension.

  2013cites this paper